Hugo Robotic Prostatectomy in an Ambulatory Surgery Center
Official title: A Single-center Study of Robotic Prostatectomy Surgeries Performed Using the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in an Ambulatory Surgical Center Setting
Run by Central Ohio Urology Group · NCT07875192 · Data updated 2026-11-12
This study tests the use of the Hugo robotic system for prostate removal in adult men treated at an outpatient surgical center.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 100 (estimated) |
| Sponsor | Central Ohio Urology Group Academic / other |
| Locations | 1 site (Columbus, Ohio) |
| Status | Recruiting |
| Started | September 30, 2026 |
| Main results expected | September 30, 2028 |
| Study ends | September 30, 2028 |
| Registry record updated | October 15, 2026 |
| Trial ID | NCT07875192 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men aged 18 or older with an indication for radical prostatectomy who are suitable for robotic Hugo RAS and able to provide informed consent.
✕Probably not a fit
Patients who have contraindications to Hugo RAS or who participate in concurrent conflicting studies may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects real-world data on the use of the Hugo Robotic Assisted Surgery system for radical prostatectomy performed in an ambulatory surgery center. It analyzes clinical outcomes, operative efficiency, patient recovery, and economic metrics at a single center. The goal is to understand feasibility, learning curve, and potential benefits of performing Hugo RAS procedures in an ASC setting to support broader adoption. Eligible participants are men 18 and older who are indicated for radical prostatectomy and can undergo robotic surgery, with informed consent required. Exclusion criteria include contraindications to Hugo RAS per regulatory guidelines or participation in other conflicting investigations.
Why it matters
Potential benefit: If successful, the study could show that Hugo RAS prostatectomy in an ASC is feasible and efficient, potentially improving recovery and reducing costs.
How similar studies have gone: Previous experience with robotic-assisted systems suggests potential benefits, but data specific to Hugo RAS in an ASC is still emerging and observational.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects (male) ≥ 18 years old * Subject has been indicated for a radical prostatectomy surgical procedure * Subject is able to be treated with robotic surgery * Subject is willing to participate and consents to participate, as documented by signed Institutional Review Board (IRB) approved informed consent form Exclusion Criteria: * Contraindicated for treatment with the Hugo™ RAS System in accordance with the commercial Instructions for Use and local regulations * Subject is participating in another clinical investigation at the time of enrollment or has planned participation in another clinical investigation at any time during this study that may influence the results of this study
Where it's running
-
Central Ohio Urology Group
Columbus, Ohio, United States Recruiting
Study contacts
- Principal investigator: Ronney Abaza, MD — Central Ohio Urology Group
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery
This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.
-
Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback
Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.
-
miRNA panel test to help diagnose prostate cancer
A blood test using a microRNA panel is being tested to help diagnose prostate cancer in men who are suspected of having the disease.
-
Testing 68Ga-NYM032 PET/CT in men with newly diagnosed prostate cancer
This study tests a new PSMA-targeted PET/CT imaging agent to see if it safely and accurately locates cancer in men who have just been diagnosed with prostate cancer and are planned for surgery.
-
Multi-Modal Imaging and Digital Pathology to Predict Clinically Significant Prostate Cancer
A multi-center study tests a deep learning model that combines MRI, ultrasound, and digital pathology to see if it can predict clinically significant prostate cancer non-invasively and help guide biopsies.
-
TENS to Reduce Pain During Transperineal Prostate Biopsy
This trial tests whether adding TENS to local anesthesia can lessen pain for men undergoing a transperineal prostate biopsy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.